Accuray Incorporated (ARAY) - Total Liabilities

Latest as of December 2025: $394.59 Million USD

Based on the latest financial reports, Accuray Incorporated (ARAY) has total liabilities worth $394.59 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Accuray Incorporated cash conversion from operations to assess how effectively this company generates cash.

Accuray Incorporated - Total Liabilities Trend (2002–2025)

This chart illustrates how Accuray Incorporated's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Accuray Incorporated to evaluate the company's liquid asset resilience ratio.

Accuray Incorporated Competitors by Total Liabilities

The table below lists competitors of Accuray Incorporated ranked by their total liabilities.

Company Country Total Liabilities
Ithaca Energy PLC
LSE:ITH
UK GBX8.71 Billion
Kalray SA
PA:ALKAL
France €33.60 Million
Po Valley Energy Ltd
AU:PVE
Australia AU$3.04 Million
Malaysia Steel Works KL Bhd
KLSE:5098
Malaysia RM1.50 Billion
Ocumetics Technology Corp
V:OTC
Canada CA$5.52 Million
Reliance Securities Tbk
JK:RELI
Indonesia Rp201.29 Billion
Unlu Yatirim Holding AS
IS:UNLU
Turkey TL2.35 Billion
Enwell Energy plc
F:RHN
Germany €18.84 Million

Liability Composition Analysis (2002–2025)

This chart breaks down Accuray Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARAY market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.47 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 7.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.88 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Accuray Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Accuray Incorporated (2002–2025)

The table below shows the annual total liabilities of Accuray Incorporated from 2002 to 2025.

Year Total Liabilities Change
2025-06-30 $389.07 Million -8.14%
2024-06-30 $423.54 Million -0.47%
2023-06-30 $425.56 Million +1.40%
2022-06-30 $419.66 Million +2.04%
2021-06-30 $411.26 Million -3.75%
2020-06-30 $427.29 Million +10.04%
2019-06-30 $388.31 Million +17.64%
2018-06-30 $330.10 Million -8.29%
2017-06-30 $359.93 Million -12.08%
2016-06-30 $409.37 Million +3.85%
2015-06-30 $394.19 Million -0.62%
2014-06-30 $396.64 Million +7.46%
2013-06-30 $369.09 Million +37.06%
2012-06-30 $269.30 Million +24.99%
2011-06-30 $215.46 Million +131.41%
2010-06-30 $93.11 Million -22.72%
2009-06-30 $120.48 Million -26.64%
2008-06-30 $164.24 Million -20.53%
2007-06-30 $206.67 Million -5.84%
2006-06-30 $219.48 Million +53.45%
2005-06-30 $143.03 Million +118.72%
2003-06-30 $65.39 Million +83.92%
2002-06-30 $35.56 Million --

About Accuray Incorporated

NASDAQ:ARAY USA Medical Devices
Market Cap
$53.27 Million
Market Cap Rank
#21663 Global
#4603 in USA
Share Price
$0.47
Change (1 day)
+0.66%
52-Week Range
$0.34 - $1.85
All Time High
$7.46
About

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation t… Read more